CORE--CLINICAL TASK FORCE

核心——临床工作组

• 批准号: 3726363
• 负责人: JOHN C. MORRIS
• 金额: --
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3726363
• 关键词: Alzheimer's disease; biomedical facility; brain disorder diagnosis; cognition disorders; cooperative study; dementia; diagnosis design /evaluation; diagnosis quality /standard; human old age (65+); human subject; longitudinal human study; memory disorders; patient /disease registry; postmortem

The CERAD Clinical Task Force was established to develop a clinical assessment battery for the diagnosis and characterization of Alzheimer's disease (AD) and to standardize its administration and interpretation. In this revised application, the Task Force builds on the successful achievement of its original mission. Using unique resources developed through experience in standardizing criteria and assessment tools for probable AD across multiple centers, CERAD will continue to obtain follow- up studies of identically diagnosed and assessed subjects for longitudinal study until autopsy to determine clinical, neuropsychological, and neuropathologic findings. The data obtained will be used to examine already identified features of AD such as extrapyramidal dysfunction, and will permit examination of clinico-pathologic correlates of AD.

CERAD 临床工作组的成立是为了开发临床 用于阿尔茨海默病诊断和表征的评估组合 疾病（AD）并标准化其管理和解释。 在 在这个修订后的应用程序中，工作组建立在成功的基础上 完成了最初的使命。 利用独特的资源开发 通过标准化标准和评估工具的经验 可能的 AD 跨多个中心，CERAD 将继续获得后续信息 对相同诊断和评估的受试者进行纵向研究 研究直至尸检以确定临床、神经心理学和 神经病理学发现。 获得的数据将用于检查 已经确定了 AD 的特征，例如锥体外系功能障碍，并且 将允许检查 AD 的临床病理相关性。